Rare predicted loss-of-function variants of type I IFN immunity genes are associated with life-threatening COVID-19
ABSTRACT: Background We previously reported that impaired type I IFN activity, due to inborn errors of TLR3- and TLR7dependent type I interferon (IFN) immunity or to autoantibodies against type I IFN, account for 15–20% of cases of life-threatening COVID-19 in unvaccinated patients. Therefore, the d...
- Autores:
-
Arias Sierra, Andrés Augusto
Franco Restrepo, José Luis
Matuozzo, Daniela
Talouarn, Estelle
Marchal, Astrid
Zhang, Peng
Rojas Silva, Julían
Manry, Jeremy
Seeleuthner, Yoann
Zhang, Yu
Bolze, Alexandre
Chaldebas, Matthieu
Milisavljevic, Baptiste
Gervais, Adrian
Bastard, Paul
Asano, Takaki
Bizien, Lucy
Barzaghi, Federica
Abolhassani, Hassan
Abou Tayoun, Ahmad
Aiuti, Alessandro
Ilad, Alavi Darazam
Allende, Luis M
Alonso-Arias, Rebeca
Aytekin, Gokhan
Bergman, Peter
Bondesan, Simone
Bryceson, Tenan Y.
Bustos, Ingrid G.
Cabrera-Marante, Oscar
Carcel, Sheila
Carrera, Paola
Casari, Giorgio
Chaibi, Khalil
Colobran, Roger
Condino-Neto, Antonio
Covill, Laura E.
Delmonte, Ottavia M.
El Zein, Loubna
Flores, Carlos
Gregersen, Peter K.
Gut, Marta
Haerynck, Filomeen
Halwani, Rabih
Hancerli, Selda
Hammarström, Lennart
Hatipoglu, Nevin
Karbuz, Adem
Keles, Sevgi
Kyheng, Cristele
Leon-Lopez, Rafael
Mansouri, Davood
Martinez-Picado, Javier
Ozge, Metin Akcan
Migeotte, Isabelle
Morange, Pierre-Emmanuel
Morelle, Guillaume
Martin-Nalda, Andrea
Novelli, Giuseppe
Novelli, Antonio
Ozcelik, Tayfun
Palabiyik, Figen
Pan‑Hammarström, Qiang
Perez de Diego, Rebeca
Planas-Serra, Laura
Pleguezuelo, Daniel E.
Prando, Carolina
Pujol, Aurora
Reyes, Luis Felipe
Riviere, Jacques G.
Rodriguez-Gallego, Carlos
Rovere-Querini, Patrizia
Schlüter, Agatha
Shahrooei, Mohammad
Sobh, Ali
Soler-Palacin, Pere
Tandjaoui-Lambiotte, Yacine
Tipu, Imran
Tresoldi, Cristina
Troya, Jesus
Van de Beek, Diederik
Zatz, Mayana
Zawadzki, Pawel
Al-Muhsen, Saleh Zaid
Alosaimi, Mohammed Faraj
Alsohime, Fahad M.
Baris-Feldman, Hagit
Butte, Manish J.
Constantinescu, Stefan N.
Cooper, Megan A.
Dalgard, Clifton L.
Fellay, Jacques
Heath, James R.
Lau, Yu-Lung
Lifton, Richard P.
Maniatis, Tom
Mogensen, Trine H.
von Bernuth, Horst
Lermine, Alban
Vidaud, Michel
Boland, Anne
Deleuze, Jean‑François
Nussbaum, Robert
Kahn-Kirby, Amanda
Mentre, France
Tubiana, Sarah
Gorochov, Guy
Tubach, Florence
Hausfater, Pierre
Meyts, Isabelle
Zhang, Shen-Ying
Puel, Anne
Notarangelo, Luigi D.
Boisson-Dupuis, Stephanie
Su, Helen C.
Boisson, Bertrand
Jouanguy, Emmanuelle
Casanova, Jean-Laurent
Zhang, Qian
Abel, Laurent
Cobat, Aurelie
- Tipo de recurso:
- Article of investigation
- Fecha de publicación:
- 2023
- Institución:
- Universidad de Antioquia
- Repositorio:
- Repositorio UdeA
- Idioma:
- eng
- OAI Identifier:
- oai:bibliotecadigital.udea.edu.co:10495/38898
- Acceso en línea:
- https://hdl.handle.net/10495/38898
- Palabra clave:
- Autoanticuerpos
Autoantibodies
COVID-19
Interferón Tipo I
Interferon Type I
SARS-CoV-2
Receptor Toll-Like 3
Toll-Like Receptor 3
Receptor Toll-Like 7
Toll-Like Receptor 7
Inmunidad
Immunity
https://id.nlm.nih.gov/mesh/D001323
https://id.nlm.nih.gov/mesh/D000086382
https://id.nlm.nih.gov/mesh/D007370
https://id.nlm.nih.gov/mesh/D000086402
https://id.nlm.nih.gov/mesh/D051196
https://id.nlm.nih.gov/mesh/D051199
https://id.nlm.nih.gov/mesh/D007109
- Rights
- openAccess
- License
- https://creativecommons.org/licenses/by/4.0/
| Summary: | ABSTRACT: Background We previously reported that impaired type I IFN activity, due to inborn errors of TLR3- and TLR7dependent type I interferon (IFN) immunity or to autoantibodies against type I IFN, account for 15–20% of cases of life-threatening COVID-19 in unvaccinated patients. Therefore, the determinants of life-threatening COVID-19 remain to be identifed in~80% of cases. Methods We report here a genome-wide rare variant burden association analysis in 3269 unvaccinated patients with life-threatening COVID-19, and 1373 unvaccinated SARS-CoV-2-infected individuals without pneumonia. Among the 928 patients tested for autoantibodies against type I IFN, a quarter (234) were positive and were excluded. Results No gene reached genome-wide signifcance. Under a recessive model, the most signifcant gene with at-risk variants was TLR7, with an OR of 27.68 (95%CI 1.5–528.7, P=1.1× 10−4) for biochemically loss-of-function (bLOF) variants. We replicated the enrichment in rare predicted LOF (pLOF) variants at 13 infuenza susceptibility loci involved in TLR3-dependent type I IFN immunity (OR=3.70[95%CI 1.3–8.2], P=2.1× 10−4). This enrichment was further strengthened by (1) adding the recently reported TYK2 and TLR7 COVID-19 loci, particularly under a recessive model (OR=19.65[95%CI 2.1–2635.4], P=3.4× 10−3), and (2) considering as pLOF branchpoint variants with potentially strong impacts on splicing among the 15 loci (OR=4.40[9%CI 2.3–8.4], P=7.7× 10−8). Finally, the patients with pLOF/ bLOF variants at these 15 loci were signifcantly younger (mean age [SD]=43.3 [20.3] years) than the other patients (56.0 [17.3] years; P=1.68× 10−5). Conclusions Rare variants of TLR3- and TLR7-dependent type I IFN immunity genes can underlie life-threatening COVID-19, particularly with recessive inheritance, in patients under 60 years old. |
|---|
